Medication classes
Biosimilar articles covering lower-cost biologic alternatives, approvals, switching, access, and treatment decisions in IBD. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 2 of 2 · 50 articles
Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
